Organization
Northwell Health, Great Neck, NY, United States of America
3 abstracts
Abstract
ANIFROLUMAB REDUCES DISEASE ACTIVITY IN MULTIPLE ORGAN DOMAINS IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Org: Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America, Northwell Health, Great Neck, NY, United States of America, MedImmune, Gaithersburg, United States,
Abstract
ALTERNATIVE RENAL RESPONSE DEFINITIONS IN A RANDOMIZED, CONTROLLED TRIAL OF OBINUTUZUMAB FOR PROLIFERATIVE LUPUS NEPHRITISOrg: Hôpital Pitié-Salpêtrière, Paris, France, APHP Groupe Hospitalier Henri-Mondor, Créteil, France, Hospital Clinic de Barcelona, Barcelona, Spain, Hôpital Européen Marseille, Marseille, France, Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France,
Abstract
ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Org: Northwell Health, Great Neck, NY, United States of America, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America, Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, United States, Graham Hughes Lupus Research Laboratory Division of Women's Health, London, United Kingdom, UCSD School of Medicine, La Jolla,